Resolution of Ecchymotic Lesions due to Fluoxetine and Escitalopram after Introduction of Reboxetine

Year 2015, Volume: 40 Number: Supplement 1, 90 - 93, 09.10.2015

Sibel Koçbıyık Sedat Batmaz Levent Turhan Özgür Yüncü Ali Çayköylü

https://doi.org/10.17826/cutf.95451

Abstract

Antidepressants, frequently prescribed in depression and anxiety disorders, are known to be risk factors for an increase in bleeding. Yet, unfavourable effects of selective serotonin reuptake inhibitör (SSRI) treatment on hemostasis have rarely been reported. The most frequently reported side effects of SSRIs on the hematologic system are prolonged bleeding time, impaired thrombocyte aggregation and activity. Here we present a case in whom ecchymotic lesions occurred with esscitalopram and fluoxetine and resolved with reboxetine.

Keywords

SSRI, ecchymotic lesion, bleeding

Fluoksetin ve Essitalopram Tedavisi Sonrası Gelişen Ekimotik Lezyonların Reboksetin Tedavisi ile Düzelmesi

Abstract

Depresyon ve anksiyete bozukluklarında sıklıkla reçete edilen antidepresanların kanama riskini artırdığı bilinmektedir. Yine de seçici serotonin geri alım engelleyicisi (SSGE) tedavisinin hemostaz üzerine olan istenmeyen etkileri nadiren araştırılmıştır. SSGE’lerin hematolojik sistem üzerindeki en sık yan etkileri kanama zamanında uzama, trombosit agregasyonu ve aktivitesinde bozulmadır. Bu yazıda essitalopram ve fluoksetin ile ekimotik lezyonlar ortaya çıkıp reboksetin ile gerileyen bir olgu sunulacaktır

Keywords

SSGİ, ekimotik lezyon, kanama

References

• Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci 2007;9:47–59.
• Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, Aronoff GR. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985;46:14–9.
• Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, Parikh SV, Patten SB, Ravindran AV; Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009;117:26-43.
• Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost. 2004;91:119–28.
• Bakish D, Cavazzoni P, Chudzik J, Ravindran A Hrdina PD. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder. Biol Psychiatry. 1997;41:184– 90.
• Maurer-Spurej E. Serotonin reuptake inhibitors and cardiovascular diseases: a platelet connection. Cell Mol Life Sci. 2005;62:159–70.
• Sarma A, Horne MK 3rd. Venlafaxine-induced ecchymoses and impaired platelet aggregation. Eur J Haematol. 2006;77:533–7.
• Serebruany VL, Gurbel PA, O’Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res. 2001;43:453–62.
• Hallbäck I, Hägg S, Eriksson AC, Whiss PA. In vitro effects of serotonin and noradrenaline reuptake inhibitors on human platelet adhesion and coagulation. Pharmacol Rep. 2012;64:979-83.
• Tharmapathy P, Selheim F, Odegaard K, Lund A, Holmsen H. Venlafaxine treatment stimulates blood platelet activity. J Clin Psychopharmacol. 2000;20:589–90.
• De Abajo FJ, Garcia-Rodriguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid- suppressing agents. Arch Gen Psychiatry. 2008;65:795–803.
• Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor ntagonist therapy: a new look. Br J Clin Pharmacol. 2008;66:76–81.
• McCloskey DJ, Postolache TT, Vittone BJ, Nghiem KL, Monsale JL, Wesley RA, Rick ME. Selective serotonin reuptake inhibitors: measurement of effect on platelet function. Transl Res. 2008;151:168–72.